<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02167139</url>
  </required_header>
  <id_info>
    <org_study_id>SB5-G31-RA</org_study_id>
    <nct_id>NCT02167139</nct_id>
  </id_info>
  <brief_title>A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy</brief_title>
  <official_title>A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Immunogenicity of SB5 Compared to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Bioepis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Bioepis Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, double-blind, parallel group, multicentre clinical study to evaluate
      the efficacy, safety, tolerability, pharmacokinetics and immunogenicity of SB5 compared to
      Humira® in subjects with moderate to severe RA despite MTX therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigational product: SB5 40 mg (0.8 mL of 50 mg/mL) Indication studied: Rheumatoid
      arthritis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>American College of Rheumatology 20% Response Criteria (ACR20)</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR20</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology 50% Response Criteria (ACR50)</measure>
    <time_frame>Week 24, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score Based on a 28 Joint Count (DAS28)</measure>
    <time_frame>Week 24, Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">544</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>SB5 (proposed biosimilar to adalimumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SB5 40 mg every other week via subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humira (adalimumab)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Humira 40 mg every other week via subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humira (adalimumab)</intervention_name>
    <arm_group_label>Humira (adalimumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB5 (proposed biosimilar to adalimumab)</intervention_name>
    <arm_group_label>SB5 (proposed biosimilar to adalimumab)</arm_group_label>
    <arm_group_label>Humira (adalimumab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are male or female aged 18-75 years at the time of signing the informed consent form.

          -  Have been diagnosed as having RA according to the revised 1987 American College of
             Rheumatology (ACR) criteria for at least 6 months but not exceeding 15 years prior to
             Screening.

          -  Have moderate to severe active disease despite MTX therapy defined as:

               1. More than or equal to six swollen joints and more than or equal to six tender
                  joints (from the 66/68 joint count system) at Screening and Randomisation.

               2. Either erythrocyte sedimentation rate (Westergren) ≥ 28 mm/h or serum C-reactive
                  protein ≥ 10 mg/dL at Screening.

          -  Must have been treated with MTX for a total of at least 6 months prior to
             Randomisation and must have been on both: a stable route of administration (oral or
             parenteral) and stable dose of MTX (10-25 mg/week) for at least 4 weeks prior to
             Screening.

          -  Female subjects who are not pregnant or nursing at Screening and Randomisation and who
             are not planning to become pregnant from Screening until 5 months after the last dose
             of IP.

        Exclusion Criteria:

          -  Have been treated previously with any biological agents including any tumour necrosis
             factor inhibitor.

          -  Have a known hypersensitivity to human immunoglobulin proteins or other components of
             Humira or SB5.

          -  Have a positive serological test for hepatitis B or hepatitis C or have a known
             history of infection with human immunodeficiency virus.

          -  Have a current diagnosis of active tuberculosis (TB), have been recently exposed to a
             person with active TB, or are considered to have latent TB.

          -  Have had a serious infection or have been treated with intravenous antibiotics for an
             infection within 8 weeks or oral antibiotics within 2 weeks prior to Randomisation.

          -  Have a history of chronic or recurrent infection.

          -  Have any of the following conditions:

               1. History of congestive heart failure (New York Heart Association Class III/IV).

               2. History of acute myocardial infarction or unstable angina within the previous 12
                  months prior to Screening.

               3. History of demyelinating disorders.

               4. History of any malignancy within the previous 5 years prior to Screening.

               5. History of lymphoproliferative disease including lymphoma.

               6. Any other disease or disorder which, in the opinion of the Investigator, will put
                  the subject at risk if they are enrolled.

          -  Have physical incapacitation (ACR functional Class IV or wheelchair-/bed-bound).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asta Baranauskaite, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital of Lithuanian University of Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lithuania</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2014</study_first_submitted>
  <study_first_submitted_qc>June 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2014</study_first_posted>
  <results_first_submitted>November 22, 2016</results_first_submitted>
  <results_first_submitted_qc>November 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 19, 2017</results_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis, Adalimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SB5 (Proposed Biosimilar to Adalimumab)</title>
          <description>SB5 40 mg every other week via subcutaneous injection SB5 (proposed biosimilar to adalimumab)</description>
        </group>
        <group group_id="P2">
          <title>Humira (Adalimumab)</title>
          <description>Humira 40 mg every other week via subcutaneous injection to Week 24, then randomised again in a 1:1 ratio to either continue on Humira® 40 mg (Humira®/Humira®) or be transitioned to SB5 40 mg (Humira®/SB5) every other week up to Week 50.</description>
        </group>
        <group group_id="P3">
          <title>Humira (Adalimumab), Switch to SB5</title>
          <description>From Week 24, SB5 40 mg (Humira®/SB5) every other week up to Week 50.</description>
        </group>
        <group group_id="P4">
          <title>Humira (Adalimumab), Continue as Humira</title>
          <description>From Week 24, Humira® 40 mg (Humira®/Humira®) every other week up to Week 50.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomised, Double-blind</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="271"/>
                <participants group_id="P2" count="273"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="254"/>
                <participants group_id="P2" count="254"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Transition-extension</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="254"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="125"/>
                <participants group_id="P4" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="248"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="117"/>
                <participants group_id="P4" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SB5 (Proposed Biosimilar to Adalimumab)</title>
          <description>SB5 40 mg every other week via subcutaneous injection
SB5 (proposed biosimilar to adalimumab)</description>
        </group>
        <group group_id="B2">
          <title>Humira (Adalimumab)</title>
          <description>Humira 40 mg every other week via subcutaneous injection
Humira (adalimumab)
SB5 (proposed biosimilar to adalimumab)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="271"/>
            <count group_id="B2" value="273"/>
            <count group_id="B3" value="544"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.8" spread="12.67"/>
                    <measurement group_id="B2" value="52.5" spread="11.91"/>
                    <measurement group_id="B3" value="51.2" spread="12.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="217"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="441"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>American College of Rheumatology 20% Response Criteria (ACR20)</title>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SB5 (Proposed Biosimilar to Adalimumab)</title>
            <description>SB5 40 mg every other week via subcutaneous injection up to Week 24</description>
          </group>
          <group group_id="O2">
            <title>Humira (Adalimumab)</title>
            <description>Humira 40 mg every other week via subcutaneous injection up to Week 24</description>
          </group>
        </group_list>
        <measure>
          <title>American College of Rheumatology 20% Response Criteria (ACR20)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4"/>
                    <measurement group_id="O2" value="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR20</title>
        <time_frame>Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SB5 (Proposed Biosimilar to Adalimumab)</title>
            <description>SB5 40 mg every other week via subcutaneous injection SB5 (proposed biosimilar to adalimumab)</description>
          </group>
          <group group_id="O2">
            <title>Humira (Adalimumab), Switch to SB5</title>
            <description>From Week 24, SB5 40 mg (Humira®/SB5) every other week up to Week 50.</description>
          </group>
          <group group_id="O3">
            <title>Humira (Adalimumab), Continue as Humira</title>
            <description>From Week 24, Humira® 40 mg (Humira®/Humira®) every other week up to Week 50.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR20</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9"/>
                    <measurement group_id="O2" value="81.1"/>
                    <measurement group_id="O3" value="71.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>American College of Rheumatology 50% Response Criteria (ACR50)</title>
        <time_frame>Week 24, Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SB5 (Proposed Biosimilar to Adalimumab) at Week 24</title>
            <description>SB5 40 mg every other week via subcutaneous injection SB5 (proposed biosimilar to adalimumab)</description>
          </group>
          <group group_id="O2">
            <title>Humira (Adalimumab) at Week 24</title>
            <description>Humira 40 mg every other week via subcutaneous injection to Week 24, then randomised again in a 1:1 ratio to either continue on Humira® 40 mg (Humira®/Humira®) or be transitioned to SB5 40 mg (Humira®/SB5) every other week up to Week 50.</description>
          </group>
          <group group_id="O3">
            <title>SB5 (Proposed Biosimilar to Adalimumab) at Week 52</title>
            <description>SB5 40 mg every other week via subcutaneous injection SB5 (proposed biosimilar to adalimumab)</description>
          </group>
          <group group_id="O4">
            <title>Humira (Adalimumab), Switch to SB5 at Week 52</title>
            <description>From Week 24, SB5 40 mg (Humira®/SB5) every other week up to Week 50.</description>
          </group>
          <group group_id="O5">
            <title>Humira (Adalimumab), Continue as Humira at Week 52</title>
            <description>From Week 24, Humira® 40 mg (Humira®/Humira®) every other week up to Week 50.</description>
          </group>
        </group_list>
        <measure>
          <title>American College of Rheumatology 50% Response Criteria (ACR50)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="237"/>
                <count group_id="O3" value="212"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1"/>
                    <measurement group_id="O2" value="39.7"/>
                    <measurement group_id="O3" value="49.1"/>
                    <measurement group_id="O4" value="53.8"/>
                    <measurement group_id="O5" value="51.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score Based on a 28 Joint Count (DAS28)</title>
        <time_frame>Week 24, Week 52</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>SB5 (Proposed Biosimilar to Adalimumab)</title>
          <description>SB5 40 mg every other week via subcutaneous injection SB5 (proposed biosimilar to adalimumab)</description>
        </group>
        <group group_id="E2">
          <title>Humira (Adalimumab)</title>
          <description>Humira 40 mg every other week via subcutaneous injection to Week 24, then randomised again in a 1:1 ratio to either continue on Humira® 40 mg (Humira®/Humira®) or be transitioned to SB5 40 mg (Humira®/SB5) every other week up to Week 50.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Femoral hernia, obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Glioblastoma multiforme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Seminoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lumber radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Nasal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="268"/>
                <counts group_id="E2" events="34" subjects_affected="30" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="268"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>At least sixty (60) days prior to submitting or presenting a manuscript or other materials relating to the Study to a publisher, reviewer, or other outside persons, the Site shall provide to Sponsor a copy of all such manuscripts and materials, and allow Sponsor sixty (60) days to review and comment on them.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Clinical Development</name_or_title>
      <organization>Samsung Bioepis</organization>
      <phone>+82 31 8061 4534</phone>
      <email>dh01.shin@samsung.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

